Featured Oncology NewsA Cancer “Atlas” to Predict How Patients Will Fare
August 18, 2017
FDA Expands Use Of AstraZeneca/Merck Ovarian Cancer Drug
August 18, 2017
New Drug OK'd for Leukemia
August 18, 2017
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
A.I. Prizes, Coming to Healthcare, Hit $1M Mark in Cancer Contests
AstraZeneca Plunges After Setback in Crucial Lung-Cancer Drug Trial
AstraZeneca Gets Breakthrough Status For Blood Cancer Drug
Pipeline Online is the most comprehensive and up to date oncology pipeline information resource that is widely available on the web ...
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
Rochester, NY
New York, NY
Chicago, IL
Seoul, South Korea
Alexandria, VA
[via telephone or webcast]
[via telephone or webcast]
Buenos Aires, Argentina
Morgantown, WV
San Francisco, CA
[via telephone or webcast]
Thompsonville, MI
Barcelona, Spain
Nashville, TN
[via telephone or webcast]
[via telephone or webcast]
Richmond, VA
Barcelona, Spain
Singapore
Geneva, Switzerland
Atlanta, GA
San Francisco, CA
San Francisco, CA
Amsterdam, The Netherlands
San Francisco, CA
Washington, D.C.
Chicago, IL
Amsterdam, The Netherlands
Phoenix, AZ
Phoenix, AZ
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
Sneak Peek Into the ESMO 2017 Press Program
August 14th 2017 by H. Jack West, MD
It appears that while the PACIFIC trial of durvalumab consolidation after chemoradiation is being p...
Read More
Take the Generic, Patients Are Told. Until They Are ...
August 14th 2017 by Winston Wong, PharmD
The rationale is pretty simple. The branded drugs are now presenting deep rebate discounts, and bri...
Read More
Oncologists Still Avoid Discussing Cost of Care
August 10th 2017 by Thomas Marsland, MD
So I usually do not even know the exact cost of the drugs. I believe for me and many of us this is ...
Read More
Survivors of Breast Cancer Differ on Who Should Mana...
August 08th 2017 by Thomas Marsland, MD
I would tend to agree that the oncologist generally should be the one to deliver long term follow u...
Read More
First Opinion: New Online Navigator Helps Patients A...
August 08th 2017 by Thomas Marsland, MD
Thank you Reagan-Udall foundation. One of the really great things to come from my recent move to Ca...
Read More
Bayer Secures One-Two Treatment For Liver Cancer Aft...
August 07th 2017 by Dean Gesme, MD
After a decade with only sorafenib for advanced HCC, it is refreshing to have several promising new...
Read More
OBR Green